

2. (Amended) A method according to claim 1, wherein the transduced multi-potential hematopoietic stem cells are maintained under conditions such that at least about 92 to 99% of the cells in the G0 phase remain in the G0 phase for at least about two days.

Da 7. (Amended) A method according to claim 2, wherein the conditions under which the multi-potential hematopoietic stem cells are maintained include cytokine levels no greater than about 15 ng/ml IL-3, 15 ng/ml IL-6 and 1.5 ng/ml granulocyte-macrophage colony stimulating factor.

D3 13. (Amended) A method according to claim 1, wherein the transferred gene remains integrated into the genome of the multi-potential hematopoietic stem cells for at least 8 weeks.

D4 19. (Amended) A method according to claim 1, wherein the adeno-associated virus vector is vCWRHIVAPAP.

20. (Amended) A method according to claim 1, wherein the adeno-associated virus vector is vCWRHIVASVN.

21. (Amended) A method according to claim 1, wherein the adeno-associated virus vector is vCWRAP.